Endogen HP Special Precautions

Laboratory Tests: The combination of both estradiol levels and ultrasonography are useful for monitoring the growth and development of follicles, timing hCG administration, as well as minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestations.
The clinical confirmation of ovulation, is determined by: Arise in basal body temperature; Increase in serum progesterone and; Menstruation following the shift in basal body temperature.
When used in conjunction with indices of progesterone production, sonographic visualization of the ovaries will assist in determining if ovulation has occurred. Sonographic evidence of ovulation may include the following: Fluid in the cul-de-sac; Ovarian stigmata; Collapsed follicle.
Because of the subjectivity of the various tests for the determination of follicular maturation and ovulation, it cannot be overemphasized that the physician should choose tests with which he/she is thoroughly familiar.
Carcinogenesis and Mutagenesis: Long term toxicity studies in animals and in vitro mutagenicity tests have not been performed to evaluate the carcinogenic potential of Urofillitropin for injection, purified.
Use in Pregnancy & Lactation: Urofollitropin (Endogen HP) should not be administered during pregnancy. It is not known whether the drug is excreted in breast milk.
Use in Elderly: Safety and effectiveness in geriatric patients have not been established.